Rankings / Hormones & Endocrine

Estradiol (HRT — oral/transdermal/vaginal)

Hormones & Endocrine · Estrogen replacement

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

sex-hormone-replacementprescription
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Estradiol (HRT — oral/transdermal/vaginal) as B (6.8/10) based on strong evidence, strong benefit magnitude, and a varies by route — oral increases vte/stroke/gb disease risk modestly-risk safety profile.

WHI 2002 prematurely tarnished HRT — subsequent reanalyses, KEEPS, and ELITE demonstrate the 'timing hypothesis' (benefit when started within 10 years of menopause).

Studied, labeled, or reported-use context: Transdermal: 0. — Rx; not individualized guidance.

What the evidence says

WHI 2002 prematurely tarnished HRT — subsequent reanalyses, KEEPS, and ELITE demonstrate the 'timing hypothesis' (benefit when started within 10 years of menopause). 2022 NAMS Position Statement strongly affirms benefit:risk for symptomatic women. Transdermal estradiol avoids first-pass hepatic exposure and has a lower observed thrombotic signal than oral formulations. For women who can't or won't take HRT, NK3/NK1 receptor antagonists (fezolinetant, elinzanetant) are now non-hormonal alternatives specifically for vasomotor symptoms — see separate entries.

Mechanism

Primary mammalian estrogen; binds ERα/ERβ; modulates thousands of genes; transdermal route bypasses first-pass hepatic metabolism and avoids VTE/stroke elevation seen with oral estrogens

Studied, labeled, or reported dose & route

Transdermal: 0.025-0.1 mg/day patch or gel; oral: 0.5-2 mg/day; vaginal: 10-25 mcg tablet 2x/wk

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Estradiol (HRT — oral/transdermal/vaginal)'s effects?
Read Off Label rates the evidence for Estradiol (HRT — oral/transdermal/vaginal) as Strong and the benefit magnitude as strong, producing an overall grade of B (6.8/10). WHI 2002 prematurely tarnished HRT — subsequent reanalyses, KEEPS, and ELITE demonstrate the 'timing hypothesis' (benefit when started within 10 years of menopause).
What safety findings are reported for Estradiol (HRT — oral/transdermal/vaginal)?
Estradiol (HRT — oral/transdermal/vaginal) has a varies by route — oral increases vte/stroke/gb disease risk modestly risk profile in the database. Varies by route — oral increases VTE/stroke/GB disease risk modestly; transdermal largely avoids these; breast cancer signal small and mostly requires concurrent progestin; cardiovascular effect depends on age at initiation (<60 or within 10 yr of menopause beneficial) Legal status: Rx.
What doses or routes are reported for Estradiol (HRT — oral/transdermal/vaginal)?
Transdermal: 0.025-0.1 mg/day patch or gel; oral: 0.5-2 mg/day; vaginal: 10-25 mcg tablet 2x/wk This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Estradiol (HRT — oral/transdermal/vaginal) work?
Primary mammalian estrogen; binds ERα/ERβ; modulates thousands of genes; transdermal route bypasses first-pass hepatic metabolism and avoids VTE/stroke elevation seen with oral estrogens

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.